Medimetriks Pharmaceuticals, Inc.

Otsuka Pharmaceutical Co. Ltd. ’s topical candidate for atopic dermatitis (AD) has met its endpoints in a Japanese Phase III program, setting the stage for an approval filing in this potentially large

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal in

The combination of the first-ever biologic approved for atopic dermatitis and the massive size of the indication's market has raised interest in the disease to new heights, including during the Americ

Just getting to the 2017 finish line wasn't enough for the US FDA. The agency is running through the finish line with the Center for Drug Evaluation and Research's (CDER) approval of four new molecula